Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics Price Performance
Shares of JNCE traded up $0.25 during mid-day trading on Tuesday, hitting $4.82. 529,200 shares of the company's stock were exchanged, compared to its average volume of 346,251. Jounce Therapeutics has a 52 week low of $2.76 and a 52 week high of $9.81. The company has a market cap of $249.17 million, a PE ratio of -1.88 and a beta of 1.17. The company has a 50-day simple moving average of $3.31 and a 200 day simple moving average of $5.39.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Robert W. Baird reduced their target price on Jounce Therapeutics to $5.00 in a report on Tuesday. HC Wainwright lowered their target price on Jounce Therapeutics from $15.00 to $11.00 and set a "buy" rating for the company in a research note on Friday. Piper Sandler dropped their target price on shares of Jounce Therapeutics from $17.00 to $9.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. Raymond James upgraded shares of Jounce Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price target for the company from $15.00 to $20.00 in a report on Friday, May 6th. Finally, StockNews.com upgraded shares of Jounce Therapeutics from a "sell" rating to a "hold" rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Jounce Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $12.40.